Macular Degeneration Therapeutics Market in Asia-Pacific @ http://www.researchmoz.us/macular-degeneration-therapeutics-market-in-asia-pacific-to-2019-existing-angiogenics-retain-dominance-though-high-unmet-need-remains-report.html The Report provides in-depth insights into the macular degeneration market forecast until 2019 for the Asia-Pacific (APAC) region covering the four countries of Australia, China, India and Japan.

1. Macular Degeneration Therapeutics Market in Asia-Pacific to 2019 - Existing Angiogenics Retain Dominance
Though High Unmet Need Remains
GBI Research has released its research, “ Macular Degeneration Therapeutics Market in Asia-Pacific
to 2019 - Existing Angiogenics Retain Dominance Though High Unmet Need Remains”, which
provides in-depth insights into the macular degeneration market forecast until 2019 for the Asia-Pacific
(APAC) region covering the four countries of Australia, China, India and Japan. It also covers disease
epidemiology; treatment algorithms; treatment patterns; an in-depth analysis of clinical trials including failure
rate analysis, pipeline analysis; and an analysis of deals relevant to macular degeneration. Apart from these the
report also includes a heat map for the macular degeneration marketed products.
GBI Research analysis shows that the APAC ophthalmology market for macular degeneration was valued at
$675.7m in 2012. The market is expected to grow at a Compounded Annual Growth Rate (CAGR) of 6% for
the forecast period and will reach $1,016m by 2019. Increase in the aging population and high annual cost of
therapy of the marketed drugs are expected to drive the market valuations through 2019. However, the
predominant off-label usage of Avastin for the treatment of the disease especially in developing countries like
India and China act as a major barrier for growth of the market during the forecast period.
Scope
Disease overview along with treatment algorithms and treatment usage patterns Market size and forecast for
the macular degeneration market in APAC from 2012 to 2019 Major marketed products in the APAC along
with a heat map In-depth analysis of pipeline along with clinical trial failure analysis Key drivers and
restraints that have had a significant impact on the market Key licensing and co-development agreements in
the macular degeneration market
Reasons to Buy
Align your product portfolio to the markets with high growth potential Develop market entry and expansion
strategies by identifying the potential regions and therapeutic segments poised for strong growth Devise a
more effectively tailored country strategy through the understanding of key drivers and barriers in the macular
degeneration market Develop key strategic initiatives by understanding the key focus areas and leading
companies Accelerate and strengthen your market position by identifying key companies for mergers,
acquisitions and strategic partnerships
table Of Content
1 Table Of Contents
1.1 List Of Tables
1.2 List Of Figures
Macular Degeneration Therapeutics Market in Asia-Pacific to 2019 - Existing Angiogenics Retain Dominance Though High Unmet Need Re

2. 2 Macular Degeneration Asia-pacific Market To 2019 – Introduction
2.1 Symptoms
2.2 Etiology
2.3 Pathophysiology
2.3.1 Disease Initiation
2.3.2 Disease Propagation
2.4 Classification
2.4.1 Early Amd
2.4.2 Intermediate Amd
2.4.3 Advanced Amd
2.5 Co-morbidities And Complications
2.6 Diagnosis
2.6.1 History
2.6.2 Examination
2.6.3 Diagnostic Tests
2.7 Epidemiology
2.8 Prognosis And Disease Staging
2.9 Treatment Options
2.9.1 Pharmacological
2.9.2 Treatment Algorithms And Prescribing Habits
2.9.3 Non-pharmacological Care
3 Macular Degeneration Asia-pacific Market To 2019 – Marketed Products
3.1 Therapeutic Landscape
3.1.1 Lucentis (ranibizumab) – Novartis Ag/roche (genentech)
3.1.2 Eylea (aflibercept) – Regeneron Pharmaceuticals/bayer Healthcare
3.1.3 Avastin (bevacizumab) – Genentech (roche)
3.1.4 Macugen (pegaptanib Sodium) – Valeant Pharmaceuticals/pfizer
3.1.5 Visudyne (verteporfin Injection) – Novartis Ag
3.1.6 Triamcinolone Acetonide
3.2 Comparative Efficacy And Safety
4 Macular Degeneration Asia-pacific Market To 2019 – Pipeline For Disease
4.1 Overall Pipeline
4.2 Pipeline Analysis By Molecule Type
4.3 Pipeline Analysis By Mechanism Of Action
4.4 Clinical Trials
4.4.1 Failure Rate
4.4.2 Clinical Trial Duration
4.4.3 Clinical Trial Size
4.5 Promising Drug Candidates In The Pipeline
Macular Degeneration Therapeutics Market in Asia-Pacific to 2019 - Existing Angiogenics Retain Dominance Though High Unmet Need Re

3. 4.5.1 Mc-1101 – Macuclear, Inc.
4.5.2 Kh902 (fumintide) – Chengdu Kanghong Pharmaceuticals Group Co., Ltd.
5 Macular Degeneration Asia-pacific Market To 2019 – Market Forecast To 2019
5.1 Geographical Markets
5.1.1 Apac Market
5.1.2 Australia
5.1.3 China
5.1.4 India
5.1.5 Japan
5.2 Drivers And Barriers For The Disease Market
5.2.1 Drivers
5.2.2 Barriers
6 Macular Degeneration Asia-pacific Market To 2019 – Deals And Strategic Consolidations
6.1 Deals Analysis
6.2 Major Co-development Deals
6.2.1 Sinphar Enters Into Co-development Agreement With Macuclear
6.2.2 Allergan Enters Into Co-development Agreement With Molecular Partners
6.2.3 X-body Biosciences Enters Into Co-development Agreement With Hengrui Medicine For Amd
6.2.4 Alcon Enters Into Collaboration With Astrazeneca
6.2.5 Acucela Enters Into Co-development Agreement With Otsuka Pharma For Acu-4429
6.3 Major Licensing Deals
6.3.1 Allegro Ophthalmics Enters Into Licensing Agreement With Senju Pharma To Develop Integrin Peptide
Therapy
6.3.2 Allergan Enters Into Licensing Agreement With Molecular Partners
6.3.3 Panoptica Enters Into Licensing Agreement With Osi Pharma
6.3.4 Lpath Enters Into Licensing Agreement With Pfizer
6.3.5 Shionogi Enters Into Licensing Agreement With Oncotherapy Science
7 Macular Degeneration Asia-pacific Market To 2019 – Appendix
7.1 All Pipeline Drugs By Phase
7.1.1 Discovery
7.1.2 Preclinical
7.1.3 Ind-filed And Phase 0
7.1.4 Phase I
7.1.5 Phase Ii
7.1.6 Phase Iii
7.1.7 Undisclosed
7.2 Market Forecasts To 2019
Macular Degeneration Therapeutics Market in Asia-Pacific to 2019 - Existing Angiogenics Retain Dominance Though High Unmet Need Re

4. 7.2.1 Asia-pacific
7.2.2 Australia
7.2.3 China
7.2.4 India
7.2.5 Japan
7.3 Market Definitions
7.4 Abbreviations
7.5 References
7.6 Research Methodology
7.6.1 Coverage
7.6.2 Secondary Research
7.6.3 Primary Research
7.6.4 Therapeutic Landscape
7.6.5 Geographical Landscape
7.6.6 Pipeline Analysis
7.7 Expert Panel Validation
7.8 Contact Us
7.9 Disclaimer
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research
reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our
huge collection of market research reports. We provide our services to all sizes of organizations and across all
industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as
publishers and will assist you in making an informed decision by giving you unbiased and deep insights on
which reports will satisfy your needs at the best price.
Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
Macular Degeneration Therapeutics Market in Asia-Pacific to 2019 - Existing Angiogenics Retain Dominance Though High Unmet Need Re